Core Insights - Bausch Health reported a consolidated adjusted EBITDA of $1.05 billion for Q4 2025, a 13% increase, and $3.54 billion for the full year, a 7% increase [1][2] - The company achieved consolidated revenues of $10.27 billion for the full year 2025, up 7% on a reported basis and 5% on an organic basis [1][2] - The fourth quarter revenues reached $2.80 billion, reflecting a 9% increase on a reported basis and a 6% increase on an organic basis compared to Q4 2024 [1][2] Financial Performance - The consolidated net loss attributable to Bausch Health for Q4 2025 was $112 million, compared to a net income of $93 million in Q4 2024 [2] - For the full year 2025, the company reported a net income of $157 million, a significant improvement from a net loss of $46 million in 2024 [2] - Consolidated operating income for Q4 2025 was $474 million, down from $558 million in Q4 2024, primarily due to a goodwill impairment charge of $145 million [2] Segment Performance - The Salix segment reported revenues of $693 million for Q4 2025, a 9% increase, and $2.58 billion for the full year, an 11% increase [1][2] - The International segment generated $306 million in Q4 2025, a 10% increase, and $1.13 billion for the full year, a 2% increase [1][2] - The Bausch + Lomb segment reported revenues of $1.41 billion for Q4 2025, a 10% increase, and $5.10 billion for the full year, a 6% increase [2] Cash Flow and Debt Management - The company generated $495 million in cash from operating activities in Q4 2025, down from $601 million in Q4 2024 [2] - Total cash provided by operating activities for the full year was $1.40 billion, compared to $1.60 billion in 2024 [2] - Bausch Health executed a $1.7 billion debt exchange offer in Q4 2025, extending debt maturities to 2032 [1][2] Strategic Developments - The acquisition of Shibo's full-service aesthetics distribution business in China was completed on December 1, 2025, enhancing the company's market presence [1] - The company continues to focus on strengthening its balance sheet and enhancing shareholder value [2] - Bausch Health is committed to operational excellence and expanding its portfolio as it moves into 2026 [1][2]

International ® NEUROSCIENCE ©2025 Bausch Health Companies Inc. and/or one of its affiliates. JPMorgan Healthcare Conference January 14, 2026 Forward-Looking Statements; Non-GAAP Information Forward-Looking Statements This presentation contains forward-looking information and statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to Baus ...

Core Insights - Edgewise Therapeutics, Inc. has appointed Christopher Martin, a biotechnology veteran, to its Board of Directors, enhancing its leadership team as it prepares for significant product launches [1][2][3] Company Overview - Edgewise Therapeutics is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions, with a strong emphasis on muscle physiology [4] - The company is advancing its lead product, Sevasemten, which is in late-stage clinical trials for Becker and Duchenne muscular dystrophies, and is also developing EDG-7500 and EDG-15400 for cardiac conditions [4] Leadership Background - Christopher Martin previously served as Chief Commercial Officer for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October 2025, and has extensive experience in building commercial organizations and launch strategies [3] - His past roles include Executive Director of Marketing at SK Life Science and Head of Marketing at Cempra, where he led the development and launch strategies for multiple products [3]

Financial Performance - Bausch Health (excl B+L) achieved its 10th consecutive quarter of revenue and Adjusted EBITDA growth[18] - BHC (Excl B+L) reported revenue growth of 7% and organic revenue growth of 5% in 3Q25, reaching $1400 million[20] - BHC (Excl B+L) Adjusted EBITDA increased by 7% in 3Q25, including an $81 million Acquired IPR&D charge, reaching $773 million[21] - Consolidated revenue increased by 7% to $2681 million in 3Q25, with organic growth of 5%[26, 27] - Adjusted EBITDA attributable to Bausch Health Companies Inc increased by 8% to $986 million in 3Q25[27] - Adjusted Cash Flow from Operations was $508 million[27] Segment Performance - Salix segment reported revenue of $716 million, a 12% increase, with Xifaxan contributing significantly to growth[41, 42] - Solta Medical segment revenue increased by 25% to $140 million, driven by volume expansion across all geographies[55, 56] - Bausch + Lomb reported revenue of $1281 million, a 7% increase, with single-digit growth across all business segments[67] Guidance - The company raised its full-year 2025 Adjusted Operating Cash Flow guidance for Bausch Health (Excl B+L) to $0975 - $1025 billion[74]

2Q 2025 Earnings July 30, 2025 forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward- looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, unless required by law. The guidance in this presentation is only effective as of the date given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or r ...